The use of the SGLT2 inhibitor dapagliflozin is also currently being evaluated in the Dapagliflozin and Effect on Cardiovascular Events in Acute HF (DAPA ACT HF) trial.22 This evidence concerns the gene SLC5A2 and hydrops fetalis.